1. Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive protein (CRP) levels under treatment (responders, i.e.
Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive protein (CRP) levels under treatment (responders, i.e. CRP ≤5 mg·L−1; ––––) versus nonresponders (i.e. CRP ≥5 mg·L−1; ······) (p<0.05). b) CRP levels in patients treated with prostacyclin analogues versus patients treated with another drug (p = 0.01). ––––: geometric means. c) Proportion of patients treated with prostacyclin analogues versus another drug among the responders (□) and nonresponders (▓) (p = 0.002). Reproduced from [28] with permission from the publisher.
M. Delcroix et al. Eur Respir Rev 2009;18:
©2009 by European Respiratory Society